ABCG2 and cancer: Notably, next-generation EIs, such as tariquidar (a P-gp inhibitor) and Ko143 (a BCRP inhibitor), have demonstrated potential in restoring the efficacy of chemotherapeutic regimens, offering a new avenue for overcoming treatment failures in resistant cancer cells (Weidner et al., 2016; Lustig et al., 2022).